Effect of intravitral injection of tissue plasminogen activator on visual acuity and retinal macular thickness

Visual acuity and central macular thickness in the hemorrhagic choroid neo-vascularization due to age-related macular degeneration with intravitreal Avastin injection compared with intravitreal injection of tissue plasminogen activator with avastin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201511064166N6

Enrollment

Registered

2016-03-31

Start date

2016-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age related macular degeneration. Degeneration of macula and posterior pole

Interventions

Intervention 1: Intravitreal injection of 75 micrograms of tissue plasminogen activator plus 1.25 mg of Avastin in the intervention group. Intervention 2: intravitreal injection of 1.25 mg Avastin in

Treatment - Drugs

Intravitreal injection of 75 micrograms of tissue plasminogen activator plus 1.25 mg of Avastin in the intervention group

intravitreal injection of 1.25 mg Avastin in the control group (standard treatment)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: hemoragic CNV due to AMD; early onset of symptom in the last month; history of good visual acuity in affected eye Exclusion criteria: history of vitroretinal surgery; uveitis with vitroretinal impairment; corneal disease for example keratoconous, dystrophy and degeneration; any medial hazeness for example vitrous hemorrhage, significant cataract ,...; pathologic myopia; diabetic retinopathy macular edema, retinal detachment, retinal vascular disorder; significant optic nerve injury

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Visual acuity. Timepoint: Before the intervention, one month and 6 months later. Method of measurement: Snellen chart.;Macular thickness. Timepoint: Prior to the study, one month and six months later. Method of measurement: Macular OCT.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRahman Beyrami

Tabriz University of Medical Sciences

rahman.beyrami61@gmail.com+98 41 3657 7330

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026